Lucid Diagnostics Q2 2024 Adj EPS $(0.20) Beats $(0.22) Estimate, Sales $976.00K Miss $1.23M Estimate
Portfolio Pulse from Benzinga Newsdesk
Lucid Diagnostics (NASDAQ:LUCD) reported Q2 2024 adjusted EPS of $(0.20), beating the $(0.22) estimate, but missed sales expectations with $976K against the $1.23M estimate. EPS improved by 13.04% YoY, while sales surged by 513.84% YoY.
August 12, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Lucid Diagnostics reported better-than-expected EPS for Q2 2024 but missed sales estimates. EPS improved by 13.04% YoY, and sales increased significantly by 513.84% YoY.
The better-than-expected EPS is a positive sign, but the significant miss on sales estimates could offset this. The YoY improvements in both EPS and sales are notable, but the mixed results may lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100